UK markets closed

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.1000+0.3400 (+12.32%)
At close: 04:00PM EDT
3.0900 -0.01 (-0.32%)
After hours: 05:28PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 166.16M
Enterprise value -34.82M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.87
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.57

Trading information

Stock price history

Beta (5Y monthly) 1.64
52-week change 3-74.67%
S&P500 52-week change 3-1.04%
52-week high 313.1800
52-week low 32.3550
50-day moving average 33.7083
200-day moving average 35.8514

Share statistics

Avg vol (3-month) 3829.61k
Avg vol (10-day) 3585.41k
Shares outstanding 558.3M
Implied shares outstanding 6N/A
Float 847.35M
% held by insiders 11.79%
% held by institutions 169.10%
Shares short (12 May 2022) 42.9M
Short ratio (12 May 2022) 43.55
Short % of float (12 May 2022) 46.12%
Short % of shares outstanding (12 May 2022) 44.98%
Shares short (prior month 13 Apr 2022) 42.69M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-20.90%
Return on equity (ttm)-39.95%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -61.61M
Net income avi to common (ttm)-63.27M
Diluted EPS (ttm)-1.1060
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)151.87M
Total cash per share (mrq)2.61
Total debt (mrq)15.89M
Total debt/equity (mrq)8.33
Current ratio (mrq)13.60
Book value per share (mrq)3.27

Cash flow statement

Operating cash flow (ttm)-41.96M
Levered free cash flow (ttm)-34.37M